期刊
SCIENTIFIC REPORTS
卷 8, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-018-23733-4
关键词
-
资金
- NHMRC
- National Breast Cancer Foundation
- Cancer Australia
- National Institute of Health (USA)
- Breast Cancer Now
- Institute of Cancer Research
- NHS
- Cancer Research UK [C1287/A16563, C1287/A10118, C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956]
- European Union's Horizon Research and Innovation Programme [634935, 633784]
- European Community's Seventh Framework Programme [223175, HEALTH-F2-2009-223175]
- Dutch Cancer Society [NKI 2007-3839, 2009 4363, RUL 1997-1505, DDHK 2004-3124, DDHK 2009-4318]
- Instituto de Salud Carlos III
- Red Tematica de Investigation Cooperativa en Cancer
- Asociacion Espanola Contra el Cancer
- Fondo de Investigation Sanitario [PI11/00923, PI12/00070]
- Baden Wurttemberg Ministry of Science, Research and Arts
- German Cancer Aid (Deutsche Krebshilfe)
- Helsinki University Central Hospital Research Fund
- Academy of Finland [266528]
- Finnish Cancer Society
- Nordic Cancer Union
- Sigrid Juselius Foundation
- special Government Funding (EVO) of Kuopio University Hospital grants
- Cancer Fund of North Savo
- Finnish Cancer Organizations
- University of Eastern Finland
- Queensland Cancer Fund
- Cancer Council of New South Wales
- Cancer Council of Victoria
- Cancer Council of Tasmania
- Cancer Council of South Australia
- Cancer Foundation of Western Australia
- United States Army Medical Research and Materiel Command [DAMD17-01-1-0729]
- Cancer Council Victoria
- Cancer Council New South Wales
- Cancer Council South Australia
- Cancer Council Tasmania
- National Health and Medical Research Council of Australia (NHMRC) [400413, 400281, 199600]
- NIH [CA192393, CA116167, CA176785]
- NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]
- Breast Cancer Research Foundation
- CTSA Grant Program from the National Center for Advancing Translational Sciences (NCATS) of the NIH [UL1 TR000135, KL2TR000136-09]
- Biobanking and Biomolecular Resources Research Infrastructure [BBMRI-NL CP16]
- Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA
- Breast Cancer Campaign [2010PR62, 2013PR044]
- Institute of Cancer Research (ICR), London
E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, > 2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据